LITS

SEC Filing Summary: Marshall Edwards, Inc. (Form 8-K)

Business Context and Reporting Period

Company: Marshall Edwards, Inc.
Filing Date: May 9, 2011 (Event Date: May 10, 2011)
Reporting Period: Current Report on Form 8-K
Context: The Company consummated an Asset Purchase Agreement dated December 21, 2010, with Novogen Limited (majority stockholder) and Novogen Research Pty Limited. The transaction involved the acquisition of assets related to isoflavonoid technology and specific drug candidates.

Key Financial Metrics and Transaction Details

Transaction Consideration: Issuance of 1,000 shares of newly-designated Series A Convertible Preferred Stock to Novogen.
Conversion Terms:

• Standard Conversion: 1 Preferred Share = 4,827 Common Shares.
• Accelerated Conversion: If a Phase II trial achieves statistical significance (p=0.05) or a Phase III trial enrolls its first patient, conversion increases to 1 Preferred Share = 9,654 Common Shares.

Call Option: The Company holds an option to purchase all unconverted Series A Preferred Stock for an aggregate cash price of $12,000,000.
Dividends/Voting: No dividends or voting rights attached to the Series A Preferred Stock.
Financial Statements: This filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It is a current report regarding a specific corporate event.

Material Changes and Terminations

Asset Acquisition: Acquired intellectual property and assets for isoflavone technology, including drug candidates Phenoxodiol, Triphendiol, NV 143, and NV-128.
Termination of Agreements: Upon consummation, the following license agreements with the Seller were terminated:

• September 2003 agreement regarding Phenoxodiol products.
• May 2006 agreement regarding oncology compounds NV-196 and NV-143.
• August 2009 agreement regarding compound NV-128.

Restrictions: Novogen is restricted from transferring Series A Preferred Stock without consent. Common stock issued upon conversion is restricted from transfer until June 30, 2011, with additional restrictions on other Novogen holdings until December 24, 2011.

Outlook, Risks, and Management Commentary

Management Action: The Company filed a Certificate of Designation for the Series A Convertible Preferred Stock with the Delaware Secretary of State on May 9, 2011.
Future Triggers: The conversion ratio of the preferred stock is contingent on clinical trial milestones (Phase II statistical significance or Phase III enrollment).
Automatic Conversion: Unconverted stock will automatically convert to common stock upon the earlier of the fifth anniversary of the closing or a "change in control" of Novogen.
Risks/Contingencies: The filing does not explicitly list new risks beyond the standard contingencies of clinical trial outcomes affecting the equity structure.

Key Facts for Investor Verification

• Verify the exact number of common shares outstanding post-conversion if the accelerated trigger is met (potential dilution of 9,654,000 shares).
• Confirm the Company's cash position relative to the $12,000,000 call option on the preferred stock.
• Review the status of clinical trials for Phenoxodiol, Triphendiol, NV 143, and NV-128 to assess the likelihood of accelerated conversion.
• Check for any subsequent filings regarding the transfer restrictions on Novogen's holdings.
• Verify the termination of the legacy license agreements to ensure no lingering royalty obligations exist.